Journal of Istanbul Faculty of Medicine

SUBMITINFORMATION
EnglishTürkçe

Original Research


DOI :https://doi.org/10.18017/iuitfd.78568   IUP :https://doi.org/10.18017/iuitfd.78568    Full Text (PDF)

SERUM TRANSFORMİNG GROWTH FACTOR BETA 1 (TGF-Β1) LEVELS IN PANCREATIC ADENOCARCINOMA PATIENTS

Senem Karabulut, Mehmet Karabulut, Çiğdem Usul Afşar, Halil Alış, Nergiz Dağoğlu, Cevher Akarsu, Kayhan Ertürk, Elif Bilgin, Faruk Taş

Objective: The transforming growth factor beta 1 (TGF-β1) is a regulatory cytokine in many tumors. In this study, we aimed to determine the clinical significance of serum TGF- β1 levels in patients with pancreatic adenocarcinoma (PA).

Materials and Methods: Thirty-three patients with a histopathologically confirmed PA diagnosis and sex- and age-matched 30 healthy controls were included into the current study. Serum TGF-β1 levels were measured using the ELISA method.

Results: Median age was 59 (range, 32-84). Of the patients, 61% were male, 70% had good performance status, and 68% had tumors localized at the head of the pancreas. Pancreaticoduodenectomy and palliative surgery were performed in 5 (15%) and 4 (12%) of the 9 (27%) patients who underwent surgical procedure. Serum TGF-β1 levels were found to be significantly higher in patients compared with the control group (p<0.001). A significant correlation between serum TGF-β1 levels and clinico-pathological parameters including age, gender, performance status, tumor locatization, tumor size, metastasis, chemotherapy response, and laboratory parameters was not detected (p>0.05). High

TGF-β1 levels seems to predict better survival (p=0.09) although it was not found significant.

Conclusions: Serum TGF-β1 level is a diagnostic biomarker for patients with PA. However, it has neither predictive nor prognostic value in this group of patients.

Keywords: Pancreatic adenocarcinoma, TGF-β1, diagnosis
DOI :https://doi.org/10.18017/iuitfd.78568   IUP :https://doi.org/10.18017/iuitfd.78568    Full Text (PDF)

PANKREAS ADENOKARSİNOMLU HASTALARDA SERUM TRANSFORME EDİCİ BÜYÜME FAKTÖR BETA 1 (TGF-Β1) DÜZEYLERİ

Senem Karabulut, Mehmet Karabulut, Çiğdem Usul Afşar, Halil Alış, Nergiz Dağoğlu, Cevher Akarsu, Kayhan Ertürk, Elif Bilgin, Faruk Taş

Amaç: Transforme edici büyüme faktör beta 1 (TGF-β1) birçok tümör tipinde regülatör bir sitokindir. Bu çalışmada, pankreas adenokarsinomlu (PA) hastalarda serum TGF-β1 düzeylerinin klinik önemininin belirlenmesi amaçlanmıştır.

Gereç ve Yöntem: Çalışmamıza histopatolojik olarak tanısı doğrulanmış 33 PA’lı hasta ile yaş-cinsiyet olarak eşleştirilmiş 30 sağlıklı kontrol alındı. Serum TGF-β1 düzeyleri, ELISA yöntemiyle belirlendi.

Bulgular: Ortanca teşhis yaşı 59 (aralık, 32-84) idi. Hastaların %61'i erkek, %70’inin performans durumu iyi ve %68’inde tümör lokalizasyonu pankreas başı bölgesindeydi. Cerrahi uygulanan 9 (%27) hastanın; 5 (%15)’ine pankreatikoduodenektomi operasyonu, 4 (%12)’üne ise palyatif cerrahi uygulandı. Serum TGF-β1düzeyleri, hasta grubunda kontrol grubuna göre anlamlı olarak yüksek bulundu (p<0.001). Serum TGF-β1 düzeyleri ile yaş, cinsiyet, performans durumu, tümör lokalizasyonu, tümör büyüklüğü, metastaz varlığı, kemoterapi cevabı ve laboratuvar parametrelerini de içeren klinikopatolojik parametreler arasında anlamlı bir korelasyon saptanmadı (p>0.05). Yüksek serum TGF-β1 düzeyleri, iyi prognozu predikte edebilir ancak istatistiksel anlamlılık bulunmamıştır (p=0.09).

Sonuçlar: Serum TGF-β1, PA’lı hastalarda tanısal biyobelirteçtir. Fakat, prediktif ve prognostik değeri mevcut değildir.

Keywords: Pankreas adenokanser, TGF-β1, tanı

PDF View

References

  • Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. CA Cancer J. Clin 2008;58:71-96. google scholar
  • Ansari D, Rosendahl A, Elebro J, Andersson R. Systematic review of immunohistochemical biomarkers to identify prognostic subgroups of patients with pancreatic cancer. Br J Surg 2011;98(8):1041-55. google scholar
  • Sheen-Chen SM, Chen HS, Sheen CW, Eng HL, Chen WJ. Serum levels of transforming growth factor b1 in patients with breast cancer. Arch Surg 2001;136:937–40 google scholar
  • Shim KS, Kim KH, Han WS, Park EB. Elevated serum levels of transforming growth factor-b1 in patients with colorectal carcinoma. Cancer 1999;85:554–61 google scholar
  • Tas F, Yasasever CT, Karabulut S, Tastekin D, Duranyildiz D. Serum transforming growth factorbeta1 levels may have predictive and prognostic roles in patients with gastric cancer. Tumour Biol 2015;36(3):2097-103 google scholar
  • Ivanovic V, Melman A, Davis-Joseph B, Valcic M, Geliebter J. Elevated plasma levels of TGF-b1 in patients with invasive prostate cancer. Nat Med 1995;1:282–4. google scholar
  • Tas F, Karabulut S, Yasasever CT, Duranyildiz D. Serum transforming growth factor-beta 1 (TGF-β1) levels have diagnostic, predictive, and possible prognostic roles in patients with melanoma. Tumour Biol 2014;35(7):7233-7. google scholar
  • Javle M, Li Y, Tan D, Dong X, Chang P, Kar S, et al. Biomarkers of TGF-β signaling pathway and prognosis of pancreatic cancer. PLoS One 2014;9(1):85942. google scholar
  • Lou C, Zhang F, Yang M, Zhao J, Zeng W, Fang X, et al. Naringenin decreases invasiveness and metastasis by inhibiting TGF-β-induced epithelial to mesenchymal transition in pancreatic cancer cells. PLoS One 2012;7(12):50956. google scholar
  • Song L, Wang P, Tian Y, Chang D, Li K, Fan Y, et al. Lung metastasis of pancreatic carcinoma is regulated by TGFβ signaling. Tumour Biol 2015;36(4):2271-6. google scholar
  • Kleeff J, Friess H, Simon P, Susmallian S, Büchler P, Zimmermann A, et al. Overexpression of Smad2 and colocalization with TGF-beta1 in human pancreatic cancer. Dig Dis Sci 1999;44:1793–802. google scholar
  • Hashimoto K, Nio Y, Sumi S, Toga T, Omori H, Itakura M, et al. Correlation between TGF-beta1 and p21 (WAF1/CIP1) expression and prognosis in resectable invasive ductal carcinoma of the pancreas. Pancreas 2001;22:341–47. google scholar
  • Nio Y, Omori H, Hashimoto K, Itakura M, Koike M, Yano S, et al. Immunohistochemical expression of receptor-tyrosine kinase c-kit protein and TGFbeta1 in invasive ductal carcinoma of the pancreas. Anticancer Res 2005;25:3523–29. google scholar
  • Culhaci N, Sagol O, Karademir S, Astarcioglu H, Astarcioglu I, Soyturk M, et al. Expression of transforming growth factor-beta-1 and p27Kip1 in pancreatic adenocarcinomas: relation with cellcycle-associated proteins and clinicopathologic characteristics. BMC Cancer 2005;5:98. google scholar
  • Bellone G, Smirne C, Mauri FA, Tonel E, Carbone A, Buffolino A et al. Cytokine expression profile in human pancreatic carcinoma cells and in surgical specimens: implications for survival. Cancer Immunol Immunother 2006;55:684–98. google scholar
  • Lin Y, Kikuchi S, Tamakoshi A, Obata Y, Yagyu K, Inaba Y, et al. JACC Study Group. Serum transforming growth factor-beta1 levels and pancreatic cancer risk: a nested case-control study (Japan). Cancer Causes Control 2006;17(8):1077- 82. google scholar

Citations

Copy and paste a formatted citation or use one of the options to export in your chosen format


EXPORT



APA

Karabulut, S., Karabulut, M., Usul Afşar, Ç., Alış, H., Dağoğlu, N., Akarsu, C., Ertürk, K., Bilgin, E., & Taş, F. (2016). SERUM TRANSFORMİNG GROWTH FACTOR BETA 1 (TGF-Β1) LEVELS IN PANCREATIC ADENOCARCINOMA PATIENTS. Journal of Istanbul Faculty of Medicine, 79(1), 9-15. https://doi.org/https://doi.org/10.18017/iuitfd.78568


AMA

Karabulut S, Karabulut M, Usul Afşar Ç, Alış H, Dağoğlu N, Akarsu C, Ertürk K, Bilgin E, Taş F. SERUM TRANSFORMİNG GROWTH FACTOR BETA 1 (TGF-Β1) LEVELS IN PANCREATIC ADENOCARCINOMA PATIENTS. Journal of Istanbul Faculty of Medicine. 2016;79(1):9-15. https://doi.org/https://doi.org/10.18017/iuitfd.78568


ABNT

Karabulut, S.; Karabulut, M.; Usul Afşar, Ç.; Alış, H.; Dağoğlu, N.; Akarsu, C.; Ertürk, K.; Bilgin, E.; Taş, F. SERUM TRANSFORMİNG GROWTH FACTOR BETA 1 (TGF-Β1) LEVELS IN PANCREATIC ADENOCARCINOMA PATIENTS. Journal of Istanbul Faculty of Medicine, [Publisher Location], v. 79, n. 1, p. 9-15, 2016.


Chicago: Author-Date Style

Karabulut, Senem, and Mehmet Karabulut and Çiğdem Usul Afşar and Halil Alış and Nergiz Dağoğlu and Cevher Akarsu and Kayhan Ertürk and Elif Bilgin and Faruk Taş. 2016. “SERUM TRANSFORMİNG GROWTH FACTOR BETA 1 (TGF-Β1) LEVELS IN PANCREATIC ADENOCARCINOMA PATIENTS.” Journal of Istanbul Faculty of Medicine 79, no. 1: 9-15. https://doi.org/https://doi.org/10.18017/iuitfd.78568


Chicago: Humanities Style

Karabulut, Senem, and Mehmet Karabulut and Çiğdem Usul Afşar and Halil Alış and Nergiz Dağoğlu and Cevher Akarsu and Kayhan Ertürk and Elif Bilgin and Faruk Taş. “SERUM TRANSFORMİNG GROWTH FACTOR BETA 1 (TGF-Β1) LEVELS IN PANCREATIC ADENOCARCINOMA PATIENTS.” Journal of Istanbul Faculty of Medicine 79, no. 1 (Aug. 2025): 9-15. https://doi.org/https://doi.org/10.18017/iuitfd.78568


Harvard: Australian Style

Karabulut, S & Karabulut, M & Usul Afşar, Ç & Alış, H & Dağoğlu, N & Akarsu, C & Ertürk, K & Bilgin, E & Taş, F 2016, 'SERUM TRANSFORMİNG GROWTH FACTOR BETA 1 (TGF-Β1) LEVELS IN PANCREATIC ADENOCARCINOMA PATIENTS', Journal of Istanbul Faculty of Medicine, vol. 79, no. 1, pp. 9-15, viewed 24 Aug. 2025, https://doi.org/https://doi.org/10.18017/iuitfd.78568


Harvard: Author-Date Style

Karabulut, S. and Karabulut, M. and Usul Afşar, Ç. and Alış, H. and Dağoğlu, N. and Akarsu, C. and Ertürk, K. and Bilgin, E. and Taş, F. (2016) ‘SERUM TRANSFORMİNG GROWTH FACTOR BETA 1 (TGF-Β1) LEVELS IN PANCREATIC ADENOCARCINOMA PATIENTS’, Journal of Istanbul Faculty of Medicine, 79(1), pp. 9-15. https://doi.org/https://doi.org/10.18017/iuitfd.78568 (24 Aug. 2025).


MLA

Karabulut, Senem, and Mehmet Karabulut and Çiğdem Usul Afşar and Halil Alış and Nergiz Dağoğlu and Cevher Akarsu and Kayhan Ertürk and Elif Bilgin and Faruk Taş. “SERUM TRANSFORMİNG GROWTH FACTOR BETA 1 (TGF-Β1) LEVELS IN PANCREATIC ADENOCARCINOMA PATIENTS.” Journal of Istanbul Faculty of Medicine, vol. 79, no. 1, 2016, pp. 9-15. [Database Container], https://doi.org/https://doi.org/10.18017/iuitfd.78568


Vancouver

Karabulut S, Karabulut M, Usul Afşar Ç, Alış H, Dağoğlu N, Akarsu C, Ertürk K, Bilgin E, Taş F. SERUM TRANSFORMİNG GROWTH FACTOR BETA 1 (TGF-Β1) LEVELS IN PANCREATIC ADENOCARCINOMA PATIENTS. Journal of Istanbul Faculty of Medicine [Internet]. 24 Aug. 2025 [cited 24 Aug. 2025];79(1):9-15. Available from: https://doi.org/https://doi.org/10.18017/iuitfd.78568 doi: https://doi.org/10.18017/iuitfd.78568


ISNAD

Karabulut, Senem - Karabulut, Mehmet - Usul Afşar, Çiğdem - Alış, Halil - Dağoğlu, Nergiz - Akarsu, Cevher - Ertürk, Kayhan - Bilgin, Elif - Taş, Faruk. “SERUM TRANSFORMİNG GROWTH FACTOR BETA 1 (TGF-Β1) LEVELS IN PANCREATIC ADENOCARCINOMA PATIENTS”. Journal of Istanbul Faculty of Medicine 79/1 (Aug. 2025): 9-15. https://doi.org/https://doi.org/10.18017/iuitfd.78568



TIMELINE



SHARE



Istanbul University Press aims to contribute to the dissemination of ever growing scientific knowledge through publication of high quality scientific journals and books in accordance with the international publishing standards and ethics. Istanbul University Press follows an open access, non-commercial, scholarly publishing.